Lineage Cell Therapeutics Analyst Ratings
Lineage Cell Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/24/2023 | 400% | HC Wainwright & Co. | $7 → $7 | Reiterates | Buy → Buy |
| 05/12/2023 | 400% | HC Wainwright & Co. | → $7 | Reiterates | Buy → Buy |
| 04/26/2023 | 400% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 03/10/2023 | 400% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 11/02/2022 | 257.14% | Baird | → $5 | Initiates Coverage On | → Outperform |
| 06/14/2022 | 185.71% | B. Riley Securities | → $4 | Initiates Coverage On | → Buy |
| 08/19/2021 | 471.43% | Noble Capital Markets | → $8 | Initiates Coverage On | → Outperform |
| 03/31/2021 | 328.57% | Cantor Fitzgerald | → $6 | Initiates Coverage On | → Overweight |
| 09/17/2020 | — | Noble Capital Markets | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 07/24/2023 | 400% | HC Wainwright公司 | $7→$7 | 重申 | 购买→购买 |
| 2023年05月12日 | 400% | HC Wainwright公司 | →$7 | 重申 | 购买→购买 |
| 04/26/2023 | 400% | HC Wainwright公司 | →$7 | 重申 | →购买 |
| 03/10/2023 | 400% | HC Wainwright公司 | →$7 | 重申 | →购买 |
| 11/02/2022 | 257.14% | 贝尔德 | →$5 | 开始承保 | →跑赢大盘 |
| 2022/06/14 | 185.71% | B.莱利证券 | →$4 | 开始承保 | →购买 |
| 2021/08/19 | 471.43% | 来宝资本市场 | →$8 | 开始承保 | →跑赢大盘 |
| 03/31/2021 | 328.57% | 康托·菲茨杰拉德 | →$6 | 开始承保 | →超重 |
| 09/17/2020 | - | 来宝资本市场 | 开始承保 | →跑赢大盘 |
What is the target price for Lineage Cell Therapeutics (LCTX)?
LCTX的目标价格是多少？
The latest price target for Lineage Cell Therapeutics (AMEX: LCTX) was reported by HC Wainwright & Co. on July 24, 2023. The analyst firm set a price target for $7.00 expecting LCTX to rise to within 12 months (a possible 400.00% upside). 5 analyst firms have reported ratings in the last year.
2023年7月24日，HC Wainwright&Co.报道了Lineage细胞治疗公司(美国证券交易所代码：LCTX)的最新目标价。这家分析公司将目标价定为7美元，预计LCTX将在12个月内上涨至(可能上涨400.00%)。去年有5家分析公司公布了评级。
What is the most recent analyst rating for Lineage Cell Therapeutics (LCTX)?
谱系细胞治疗公司(LCTX)的最新分析师评级是什么？
The latest analyst rating for Lineage Cell Therapeutics (AMEX: LCTX) was provided by HC Wainwright & Co., and Lineage Cell Therapeutics reiterated their buy rating.
对Lineage Cell Treateutics(美国证券交易所代码：LCTX)的最新分析师评级由HC Wainwright&Co.提供，Lineage Cell Treateutics重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Lineage Cell Therapeutics (LCTX)?
LCTX(LCTX)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lineage Cell Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lineage Cell Therapeutics was filed on July 24, 2023 so you should expect the next rating to be made available sometime around July 24, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查看公共财务报表，与Lineage Cell Treateutics的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Lineage细胞治疗公司的最后一次评级是在2023年7月24日提交的，所以你应该预计下一次评级将在2024年7月24日左右的某个时候提供。
Is the Analyst Rating Lineage Cell Therapeutics (LCTX) correct?
分析师对LCTX的评级正确吗？
While ratings are subjective and will change, the latest Lineage Cell Therapeutics (LCTX) rating was a reiterated with a price target of $7.00 to $7.00. The current price Lineage Cell Therapeutics (LCTX) is trading at is $1.40, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的LCTX评级被重申，目标价在7.00美元至7.00美元之间。目前LCTX的交易价格为1.40美元，超出了分析师的预测范围。